Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

BACKGROUND: The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3(rd )or later-...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Lièvre, Astrid, Samalin, Emmanuelle, Mitry, Emmanuel, Assenat, Eric, Boyer-Gestin, Christine, Lepère, Céline, Bachet, Jean-Baptiste, Portales, Fabienne, Vaillant, Jean-Nicolas, Ychou, Marc, Rougier, Philippe
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2761407/
https://ncbi.nlm.nih.gov/pubmed/19785749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-347
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items